Cardiovascular Biomarkers and Surrogate Endpoints Symposium
August 1-2, 2003
WELCOME, CONFERENCE OBJECTIVES - Dr. Jean-Claude Tardif and Dr. Peter Libby
Historical Perspective - Dr. Therese Heinonen
The Need for Biomarkers in Drug Development - Dr. Donald Black
PATHOLOGY OF ATHEROSCLEROSIS, Basic Mechanisms to Biomarkers - Dr. Peter Libby
GENETICS OF CAD - Dr. Daniel Gaudet
Understanding CAD using Genomics - Dr. Jamie Engert
IMAGING SESSION I
Angiography - Dr. David Waters
Carotid IMT - Dr. Daniel O’Leary
IMAGING SESSION II
Intravascular Ultrasound - Dr. Jean-Claude Tardif
Electron Beam CT Coronary Calcium as a Surrogate - Dr. Pamela Ouyang
The Case for Imaging Endpoints in Drug Approval - Dr. Steve Nissen
A REGULATORY PERSPECTIVE
A Regulatory Perspective I - Dr. David Orloff
A Regulatory Perspective II - Dr. Elizabeth Nabel
PANEL DISCUSSION CHAIRED BY DR. PETER LIBBY AND DR. JEAN-CLAUDE TARDIF
Lipids and Lipoproteins: What is New and What is on the Horizon
Overview of lipids and lipoproteins - Dr. David Waters
New targets and populations at risk - Dr. Donald Black
Classifications of Lipoproteins - Dr. Petar Alaupovic
Lipoprotein particle subclasses - Dr. James Otvos
Markers of Oxidative Stress: More Culprits
Oxidative stress 1 - Dr. Jean-Claude Tardif
Oxidative stress 2 - Dr. Sam Tsimikas
Imaging Session III
Endothelial Function - Dr. John Deanfield
Positron Emission Tomography - Dr. Marcelo Di Carli
Novel Technologies - Dr. Peter Libby
Imaging Session IV
Vascular MR and Spiral CT - Dr. Zahi Fayad
Discussion and Summary Statement